+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cetuximab"

Lung Cancer Drugs Global Market Report 2024 - Product Thumbnail Image

Lung Cancer Drugs Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
Colorectal Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Colorectal Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 550 Pages
  • Global
From
Cutaneous Squamous Cell Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Cutaneous Squamous Cell Carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 120 Pages
  • Global
From
From
Colorectal Cancer Therapeutics: Global Markets - Product Thumbnail Image

Colorectal Cancer Therapeutics: Global Markets

  • Report
  • March 2019
  • 124 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
Colorectal Cancer: Update Bulletin #1 - Product Thumbnail Image

Colorectal Cancer: Update Bulletin #1

  • Newsletter
  • May 2024
  • Global
From
Portrazza - Product Thumbnail Image

Portrazza

  • Report
  • August 2018
  • 17 Pages
  • Global
From
Loading Indicator

Cetuximab is a monoclonal antibody used in the treatment of lung cancer. It is used in combination with chemotherapy to treat non-small cell lung cancer (NSCLC). Cetuximab works by targeting the epidermal growth factor receptor (EGFR), which is found on the surface of some cancer cells. This helps to slow down or stop the growth of cancer cells. Cetuximab is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC in combination with chemotherapy. It is also approved for the treatment of metastatic colorectal cancer. Cetuximab is available in both intravenous and subcutaneous formulations. It is typically administered in combination with chemotherapy drugs such as cisplatin, carboplatin, and paclitaxel. Common side effects of cetuximab include skin rash, fatigue, nausea, and diarrhea. Some companies in the Cetuximab market include Merck & Co., Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and F. Hoffmann-La Roche Ltd. Show Less Read more